Abstract Details

Title Impact of Cardiovascular Risk over the Rate of Progression of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from Sao Paulo, Brazil

Topic Aging and Dementia

Presentation(s) P07 - (-)

Poster/Presentation
Number 136

Objective

Background BACKGROUND: Low schooling and cardiovascular risk have been implied as causative factors for AD; it is unknown whether cardiovascular risk may impact the rate of progression of AD in populations with low average schooling.

Design/Methods DESIGN/METHODS: Patients with late-onset AD according to National Institute on Aging - Alzheimer's Association criteria were recruited at the Department of Neurology and Neurosurgery of the Federal University of Sao Paulo (UNIFESP), and assessed for gender, schooling, cerebrovascular risk factors, and time since dementia onset to reach Clinical Dementia Rating (CDR) scores >1.0, and Mini-Mental State Examination (MMSE) scores of 20 and 15. Linear regression was employed for statistical analysis, with the threshold of significance set at [rho]<0.05.

Results RESULTS: A total of 146 consecutive patients were included; 103 (70.55%) were female and 43 (29.45%) were male. Mean schooling was 4.14±3.65 years (range 0-15). Mean age of AD onset was 72.9±6.1 years-old. The average time to reach CDR>1.0 (n=118) was 4.2±2.6 years; for MMSE=20 (n=143) it was 3.6±2.7 years, and for MMSE=15 (n=91) it was 4.9±2.8 years. Mean Framingham scores were 14.8±1.2 for male patients (range 11-17) and 19.8±2.5 for female patients (range 13-25). Mean 10-year cardiovascular risk was 14.3%±7.2%, higher for males (19.8%±5.1%;range 8%-30%) than for females (12.1%±6.7%;range 2%-30%). Higher Framingham scores predicted a faster progression for MMSE=15 in males ([rho]<0.001), but not in females ([rho]>0.7). Higher education was significant to female patients for later reaching MMSE=20 (F-ratio=4.35;[rho]=0.04) and MMSE=15 (F-ratio=4.99;[rho]<0.03), but not to male patients. No scores were significant for faster or slower reaching CDR>1.0.

Conclusions CONCLUSIONS: Cardiovascular risk assessed by way of Framingham scores seems to be more important for AD progression in male patients. Schooling was protective for female patients, but not for males in this sample.

Authors/Disclosures
Fabricio F. De Oliveira, MD, PhD, BBA, MSc, FAAN, FAAN (Elysian Clinic) PRESENTER	Dr. De Oliveira has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Gerson Lehrman Group. Dr. De Oliveira has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Atheneum Partners. Dr. De Oliveira has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint. Dr. De Oliveira has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lionbridge. Dr. De Oliveira has received personal compensation in the range of $0-$499 for serving as a Consultant for Coleman. Dr. De Oliveira has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. De Oliveira has received personal compensation in the range of $0-$499 for serving as a Neurology® Video Journal Club Presenter with ��ɫ��.
Tjalf Ziemssen, MD, FAAN (University Clinic Dresden)	Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS . Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Dresden Internation University. The institution of Dr. Ziemssen has received research support from Novartis. The institution of Dr. Ziemssen has received research support from Merck. The institution of Dr. Ziemssen has received research support from Sanofi. The institution of Dr. Ziemssen has received research support from BMS. The institution of Dr. Ziemssen has received research support from Roche.
Paulo Bertolucci	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ����

��ɫ����

��ɫ��

��ɫ��